How the bladder and kidneys function in children born with a blockage in the urinary tract and their current quality of life: a review of past patient data and current quality of life.

Bladder and kidney function in children with posterior urethral valves and their current quality of life; a combined retrospective and prospective cohort. - Retrospective Vesical and kidney function in a PUV cohort

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58573

Enrollment

470

Registered

2026-01-07

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posterior urethral valves, PUV, Congenital obstructing posterior urethral membrane, congenital urethral valves A blockage in the urine tube, A congenital urinary blockage,

Interventions

Not applicable&nbsp

Eligibility

Inclusion criteria

Inclusion criteria: All patients treated for posterior urethral valves in the participating centers in the last 40 years

Exclusion criteria

Exclusion criteria: None 

Design outcomes

Primary

Measure	Time frame
Main study parameters/endpoints Long term kidney function: Serum creatinine, estimated glomerular filtration rate and/or cystatine C. Long term bladder function: Incontinence, bladder overactivity.	—

Secondary

Measure	Time frame
- Bladder emptying regimen: Spontaneous, CIC, overnight catheter, vesicostomy or bladder augmentation.  - Bladder diary: Day/Night voiding frequency, voiding portions, fluid intake, incontinence (for urine or defecation)  - Uroflowmetry and postvoid residual: Bladder capacity, volume, max urinary flow, post voiding residue and flow.   - Urinary tests: Symptomatic urinary tract infection. - VUDO: Bladder pressure, voiding pressure, detrusor overactivity, bladder capacity and bladder compliance.  - Ultrasound: bladder wall thickening and upper urinary tract dilatation.  - X-MCG: Upper urinary tract dilatation, Vesicourethral reflux, diverticula and SWRD-score (12).  - PROMs: SDDESS, PedsQL, ICIQ-UI SF, SF-12 and current clinical status questionnaire.  - Medication use: anticholinergics (oral/intravesical), beta3 agonists, antibiotics - Surgical treatments: Botox, vesicostomy, ureterostomy, bladder augmentation, continent stoma	—

Measure

Time frame

- Bladder emptying regimen: Spontaneous, CIC, overnight catheter, vesicostomy or bladder augmentation.  - Bladder diary: Day/Night voiding frequency, voiding portions, fluid intake, incontinence (for urine or defecation)  - Uroflowmetry and postvoid residual: Bladder capacity, volume, max urinary flow, post voiding residue and flow.   - Urinary tests: Symptomatic urinary tract infection. - VUDO: Bladder pressure, voiding pressure, detrusor overactivity, bladder capacity and bladder compliance.  - Ultrasound: bladder wall thickening and upper urinary tract dilatation.  - X-MCG: Upper urinary tract dilatation, Vesicourethral reflux, diverticula and SWRD-score (12).  - PROMs: SDDESS, PedsQL, ICIQ-UI SF, SF-12 and current clinical status questionnaire.  - Medication use: anticholinergics (oral/intravesical), beta3 agonists, antibiotics - Surgical treatments: Botox, vesicostomy, ureterostomy, bladder augmentation, continent stoma

—

Countries

Netherlands

Contacts

Public ContactK.P. Leeuwenburgh

Erasmus MC, Universitair Medisch Centrum Rotterdam

k.leeuwenburgh@erasmusmc.nl(010) 704 01 46

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 16, 2026